Alessandro de Nicola
Chairman presso AVIO S.P.A.
Profilo
Alessandro de Nicola is currently the Chairman-Supervisory Board at Avio SpA, an Independent Director at Amundi Re Italia, and a Senior Partner at Orrick, Herrington & Sutcliffe (Italy).
He previously held positions as an Independent Non-Executive Director at Leonardo SpA and an Independent Director at AGC Biologics SpA.
Mr. de Nicola's education includes a graduate degree from Università Cattolica del Sacro Cuore Campus di Milano.
Posizioni attive di Alessandro de Nicola
| Società | Posizione | Inizio |
|---|---|---|
| AVIO S.P.A. | Chairman | - |
| NEXTRA INNXTR INV | Director/Board Member | - |
| The Adam Smith Society | President | 01/01/1993 |
Orrick, Herrington & Sutcliffe (Italy)
 Orrick, Herrington & Sutcliffe (Italy) Miscellaneous Commercial ServicesCommercial Services Part of Orrick, Herrington & Sutcliffe LLP, Orrick, Herrington & Sutcliffe (Italy) is a legal services provider. The private company is based in Milan, Italy. | Corporate Officer/Principal | - |
Precedenti posizioni note di Alessandro de Nicola
| Società | Posizione | Fine |
|---|---|---|
| LEONARDO S.P.A. | Director/Board Member | - |
| MOLMED S.P.A. | Director/Board Member | - |
Formazione di Alessandro de Nicola
| Università Cattolica del Sacro Cuore Campus di Milano | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| LEONARDO S.P.A. | Electronic Technology |
| AVIO S.P.A. | Electronic Technology |
| Aziende private | 4 |
|---|---|
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
Orrick, Herrington & Sutcliffe (Italy)
Orrick, Herrington & Sutcliffe (Italy) Miscellaneous Commercial ServicesCommercial Services Part of Orrick, Herrington & Sutcliffe LLP, Orrick, Herrington & Sutcliffe (Italy) is a legal services provider. The private company is based in Milan, Italy. | Commercial Services |
| The Adam Smith Society | |
Amundi Re Italia
 Amundi Re Italia Investment Trusts/Mutual FundsMiscellaneous Amundi Re Italia is a closed-end investment fund. The company is headquartered in Milan, Italy. | Miscellaneous |
- Borsa valori
- Insiders
- Alessandro de Nicola
